Sussex Formulary
  • About The Formulary
  • Using The Formulary
  • Therapeutic Sections
    • 1 Gastro-intestinal system
    • 2 Cardiovascular system
    • 3 Respiratory system
    • 4 Nervous system
    • 5 Infection
    • 6 Endocrine system
    • 7 Genito-urinary system
    • 8 Immune system & malignant disease
    • 9 Blood and nutrition
    • 10 Musculoskeletal system
    • 11 Eye
    • 12 Ear, nose and oropharynx
    • 13 Skin
    • 14 Vaccines
    • 15 Anaesthesia
    • 16 Emergency treatment of poisoning
    • 17 Nausea and Vomiting in Pregnancy and Hyperemesis Gravidarum
    • Appendix 1 - Borderline substances
    • Appendix 2 - Wound management products and elasticated garments
    • Appendix 3 - Continence
    • Appendix 4 - Palliative care
  • Drug Index
  • Antimicrobial Guidance
  • Shared Care Protocols
    • Sussex-wide protocols
  • Position statements
  • Not Recommended Items
  • APC Summaries
    • 2025
    • 2024
    • 2023
  • APC Minutes
    • 2021
    • 2022
    • 2023
    • 2024
    • 2025
    • 2026
  • Discontinuations
  • Contact us
  • About The Formulary
  • Using The Formulary
  • Therapeutic Sections
    • 1 Gastro-intestinal system
    • 2 Cardiovascular system
    • 3 Respiratory system
    • 4 Nervous system
    • 5 Infection
    • 6 Endocrine system
    • 7 Genito-urinary system
    • 8 Immune system & malignant disease
    • 9 Blood and nutrition
    • 10 Musculoskeletal system
    • 11 Eye
    • 12 Ear, nose and oropharynx
    • 13 Skin
    • 14 Vaccines
    • 15 Anaesthesia
    • 16 Emergency treatment of poisoning
    • 17 Nausea and Vomiting in Pregnancy and Hyperemesis Gravidarum
    • Appendix 1 - Borderline substances
    • Appendix 2 - Wound management products and elasticated garments
    • Appendix 3 - Continence
    • Appendix 4 - Palliative care
      • Pain and/or Breathlessness
      • Nausea and Vomiting
      • Agitation
      • Respiratory Secretions
  • Drug Index
  • Antimicrobial Guidance
  • Shared Care Protocols
  • Position statements
  • Not Recommended Items
  • APC Summaries
  • APC Minutes
  • Discontinuations
  • Contact us
  • Search

Drug Status Key

  • Non-Specialist Drugs
  • Specialist recommendation (or initiation where noted)
  • Specialist Initiation WITH Shared Care Guidelines
  • Specialist ONLY Drugs
  • Mixed Status - See individual drug entries for more details

Preferences

  • First Line
  • Second Line
  • Third Line
  • No Preference

Cyclizine

{ Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

Cyclizine 50mg/1ml solution for injection ampoules

Pack
5 ampoule
10 ampoule

Haloperidol

{ Value = MHRA Warning Exists, Index = 4 } { Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

Haloperidol 5mg/1ml solution for injection ampoules

Pack
5 ampoule
10 ampoule
1 ampoule

Hyoscine hydrobromide injection

{ Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

Locally Commissioned Services

Hyoscine hydrobromide 400micrograms/1ml solution for injection ampoules

Pack
10 ampoule

Hyoscine hydrobromide 600micrograms/1ml solution for injection ampoules

Pack
10 ampoule

Levomepromazine

{ Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

Levomepromazine 25mg/1ml solution for injection ampoules

Pack
10 ampoule

Levomepromazine tablets

{ Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

Levomepromazine 100mg tablets

Pack
100 tablet
28 tablet
84 tablet

Levomepromazine 25mg tablets

Pack
84 tablet
28 tablet

Levomepromazine 50mg tablets

Pack
28 tablet
84 tablet

Levomepromazine 6mg tablets

Pack
60 tablet
1 tablet
28 tablet

Online Formulary by M.O.M. Systems

NICE guidance is available from https://www.nice.org.uk/guidance All rights reserved. Subject to Notice of rights.
NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

© Copyright 2026